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Abstract
Background: To date no age-related reference ranges are available for serum thymidine kinase (TK1) activity. Being a
proliferation marker, it may be used as a prognostic marker in malignant diseases, including chronic lymphocytic leukemia
(CLL). Our aim was to establish age-specific reference ranges for TK1 and examine its utility as a screening marker in CLL, a
disease of the elderly.
Methods: Serum TK1 activity was measured by a competitive chemiluminescent immunoassay in 369 healthy adults and
115 de novo CLL patients.
Results:We observed a statistically significant decline in TK1 activity from young (18–35 years) to middle-aged (36–60 years)
and further on to elderly (60–86 years) healthy individuals. Age-related reference range was: ,30 U/L for young, ,25 U/L
for middle-aged and ,19 U/L for elderly. There was no difference in TK1 activity between the studied healthy men and
women. In CLL patients, TK1 activity was the highest in the advanced Rai stages. The area under the receiver operating
characteristic curve (ROC-AUC) for TK1 was 0.840 (95% CI: 0.787–0.892), for differentiating CLL patients from age and sex
matched healthy controls, with a cut-off value of 10.5 U/L (sensitivity: 80.9%, specificity: 73.4%). TK1 was significantly
elevated in CD38+/Zap70+ CLL patients, and showed significant correlation with WBC and absolute B-cell count.
Conclusion: In the healthy, serum TK1 activity does not differ in the two sexes but declines significantly with age. As such,
use of age-related reference ranges is warranted, especially when evaluating CLL patients who generally belong to the
elderly age group.
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Introduction
Distinguishing from a few tumor specific biomarkers (PSA, AFP,
HCG etc) [1–3], thymidine kinase 1 (TK1, ATP; thymidine 59-
phosphotransferase; EC.2.7.1.21) is one of the non-specific tumor
markers that can be measured in continuously dividing cells [4].
TK1 is a key cellular enzyme in the so-called salvage pathway of
DNA synthesis. It phosphorylates thymidine into thymidine-
monophosphate. The enzyme has two isoforms, TK1 is found in
the cytoplasm, while TK2 remains in the mitochondria. The
activity of TK1 is cell cycle-dependent, its level begins to rise in
G1/S phase and reaches its peak in the G2/M phase [5–9].
TK1 can be isolated from many different cell and tissue types,
and elevated serum TK1 activity is documented in many types of
cancer, nonetheless, the mechanism of TK entering the systemic
circulation is not well understood [10–13]. Furthermore, TK has
been reported as a prognostic marker in chronic lymphocytic
leukemia (CLL) and in non-Hodgkin’s lymphoma [14–17]. In the
last decade several studies showed the prognostic value of CD38
and Zap70 expression in CLL [18–22]. Elevated serum TK1 level
was found in patients with unmutated IGHV gene, and in those
with higher expression levels of Zap70 and CD38, as well as
advanced disease stage [23–24]. Konoplev et al showed that high
serum TK1 levels predict poorer overall survival and higher risk of
developing large B-cell lymphoma (Richter syndrome) [16]. The
first TK measurement method was a radio-enzymatic assay using
125I-deoxyuridine [25]; later a non-radiometric, competitive,
enzyme-linked, immunosorbent assay (ELISA) was developed
[26]. Wu et al developed a method for measuring not the activity
but the concentration of TK in serum [27]. Most recently, a liquid
chromatography – tandem mass spectrometry method was
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described by Faria et al [28]. Nisman et al compared two
commercially available immunoassays in breast cancer patients,
and despite reporting differences between the two assays,
concluded that both assays were adequate for tumor recurrence
prediction [29].
Hallek et al found that a serum TK level of 7.1 U/L was the
cutoff value that could differentiate shorter (high TK levels) and
longer (low TK levels) progression-free survival subgroups in Binet
A stage disease [15]. In the French-German CLL7 trial, one of the
adverse risk factors to identify high-risk Binet A patients was a
serum TK level .10 U/L [30,34]. Magnac et al examined the
relationship between serum TK levels and IGHV mutational
status and found that TK levels above 15 U/L correlated well with
the IGHV unmutated status of the patients [31]. A thorough
review on prognostic markers of CLL was published by Sagatys &
Zhang in 2012, encouraging the establishment of a universal
algorithm to improve prognostic accuracy [32]. Molica et al
carried out a comparative validation analysis of the MD Anderson
Cancer Center (MDACC) [33] and the modified German [34]
CLL score. They found that for any novel prognostic scheme,
these two scores should be the benchmark for comparison [35]. In
a recent paper, Molica suggested building an international,
comprehensive CLL prognostic index [36].
The primary aim of this study was to establish age-related
reference ranges for serum TK. Our hypothesis was that healthy
older individuals might have lower TK activity as compared to
younger adults. In addition, in a cross-sectional, case-control
study, we measured serum TK activity in de novo CLL patients who
were still therapy naı¨ve, and in an equal number of age- and sex-
matched healthy volunteers. Knowing that CLL is a disease
prevalent in the elderly, the utility of the age-specific reference
range was examined in the studied CLL cohort.
In the CLL patients, we compared the serum TK activity with
other laboratory parameters, such as white blood cell count,
absolute B cell count, CD38 and Zap70 expression.
Patients and Methods
Study population, healthy cohort for establishing
reference ranges
Healthy volunteers (n = 369) between 18 and 86 years of age
(median: 45 years, men: 157, women: 212) were recruited from
blood donors and staff of the faculty with values #26upper limit
of normal for all measured laboratory parameters. Exclusion
criteria were cancer, metabolic and inflammatory diseases. Due to
non-confirmation with selection criteria data from 24 individuals
was excluded from the final statistical analysis. To examine the
influence of age, the reference population was subgrouped into the
following age groups: 18–35 years (young), 35–60 years (middle-
aged) and 60–86 years (elderly) (Figure 1).
Study population, CLL cohort
Patients presenting with de novo CLL between December, 2010
and November, 2012 were included in this cross-sectional, analyst-
blinded, age and sex matched case-control study (n = 115). The
mean age (range) of the individuals in both groups was 65.6 (46–
86) years, and the male:female ratio was , 1:1 (61:54). As per Rai
staging, 43 were in stage Rai 0, 27 were in Rai 1, 19 were in Rai 2,
15 were in Rai 3 and 11 were in Rai 4 (Figure 1). In this cohort, 29
and 86 patients belonged to the middle-aged and elderly age-
groups, respectively.
This study was approved by the Ethics Committee of the
University of Debrecen in accordance with the Declaration of
Helsinki. All participants gave written informed consents.
Laboratory methods
Measurement of thymidine kinase activity. TK1 activity
was measured by an indirect, modified, two-step competitive
chemiluminescent immunoassay on a Liaison immunochemistry
analyzer (DiaSorin S.p.A., Saluggia, Italy). The calibration curve is
defined mathematically by the manufacturer (master curve), which
includes the pathologic values as well. For quality control the
reagent kit includes two QC samples (low and high). In order to
evaluate assay performance, accuracy and precision were deter-
mined from QC samples in low and high range (QC1 and QC2,
respectively). Precision was expressed in CV% and accuracy was
assessed as percent deviation from the nominal activity. Intra-assay
precision and accuracy were determined from 9 replicates of each
QC sample on a single occasion while inter-assay precision and
accuracy were determined by analyzing 18 different operating
days. The results were analyzed as a linear regression of the
nominal vs. observed values. Linearity was evaluated by serial
dilution of a patient sample with markedly elevated TK activity.
Determination of CD38 and Zap70 positivity of CLL
cells by flow cytometry
White blood cell counts were measured by an Advia 120
hematology analyzer (Siemens AG, Erlangen, Germany). Absolute
B-cell count was calculated from the percentage of CD19+ cells
and white blood cell count.
Flow cytometric measurements were carried out on FACS-
Canto II flow cytometer, the results were evaluated by FACSDiva
software (BD Biosciences, San Jose´, CA, USA). The antibodies
used were: CD19-PE-Cy7 (clone: J3-119, Beckman-Coulter, Brea,
CA, USA); CD38-APC (clone: HB7, BD Biosciences) and Zap70
(unlabeled, clone: 2F3.2, Merck-Millipore (Upstate), Billerica, MA,
USA). The patient was considered CD38 and/or Zap70 positive if
$20% of the CLL cells expressed the respective markers.
Fluorescence in situ hybridization (FISH). Interphase
fluorescence in situ hybridization (FISH) was performed on cell
suspension originated from peripheral blood according to standard
protocol. Cells were obtained by 72 hour culture in the presence of
12-O-tetradecanoylphorbol-13-acetate (TPA) (Sigma-Aldrich,
Munich, Germany) or by direct preparation from uncultured
peripheral blood. The probes used for FISH analysis included LSI
Rb1(13q14)/13q34, LSI p53, LSI ATM (Abbott Molecular
Inc, Des Plaines, USA). Cells were counterstained with DAPI
Figure 1. Flow diagram of study population.
doi:10.1371/journal.pone.0091647.g001
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(4,6-diamidino-2-phenylindole). At least 200 interphase cells were
analysed for each probe in each case. The images were captured
by Zeiss Axioplan2 (Carl Zeiss, Zaventem, Brussels) fluorescence
microscope and analysed by ISIS software (MetaSystems, Altlus-
sheim, Germany).
Statistical Analyses
Kolmogorov-Smirnov test was used for the evaluation of the
normality of the data. Most parameters were non-normally
distributed; therefore analyses were performed by Mann-Whitney
U test. The Spearman’s rho was calculated for correlation analysis.
P,0.05 was regarded as statistically significant. All analyses,
including drawing of receiver operating characteristic (ROC)
curves and estimation of the area under the ROC curve (AUC),
were performed using the SPSS Statistics software, version 19.0
(IBM Corps., Armonk, NY, USA).
Results
Reproducibility and accuracy tests gave excellent results. The
nominal mean TK1 activity of QC1 was 14.8 U/L. Intra-assay
measured mean was 15.061.58 U/L, precision CV of QC1 was
10.54%, accuracy was 101%. Inter-assay measured mean of QC1
was 14.862.23 U/L, precision CV was 15.03% and accuracy was
100%. The nominal mean activity of QC2 was 53.7 U/L, intra-
assay measured mean was 62.466.34 U/L, precision CV was
10.16% and accuracy was 116%. Inter-assay measured mean of
QC2 was 49.1566.27 U/L, precision CV was 12.76% and
accuracy was 92% (Table 1). The test was linear from 0.5 U/L to
100 U/L.
In the healthy cohort, there was no significant difference in TK1
activity between the men and women studied, as such gender was
not taken into consideration when defining age groups. TK1
activities of 3 age groups are shown on Figure 2A-C. There was a
significant difference between the TK1 activity of the young
(n = 95) and the elderly (n = 83), (11.8565.7 U/L vs.
8.6563.9 U/L; p,0.001) and between the young and the
middle-aged (n = 191) (11.8565.7 U/L vs. 9.7965.2 U/L;
p,0.001). The difference was at the limit of statistical significance
between the middle-aged and the elderly (9.7965.2 U/L vs.
8.6563.9 U/L; p = 0.050). Overall, the lowest observed TK1 level
was 0.5 U/L and the highest was 35.6 U/L. The 97.5 percentiles
in the 3 age groups were 29.8 U/L (young), 25.4 U/L (middle-
aged) and 19 U/L (elderly) (Figure 2D).
Results of 115 CLL patients on presentation were compared
with an equal number of age- and sex-matched controls (n = 115).
This age- and sex-matched control group was derived from the
over-all healthy cohort (n = 393), that was used to define the
reference ranges of TK1 in the different age groups. Patient
characteristics are given in Table 2. We found significant
difference in TK1 activity between the healthy control group
and all Rai stages of CLL. As we had few individuals in Rai 2, Rai
3 and Rai 4 stages, we grouped them as being in a more advanced
stage of the disease. The observed mean TK1 activity in the age
and sex matched healthy group (n = 115) was 9.1865.0 U/L,
which was significantly lower than that in Rai 0 (n = 43;
mean: 18.58615.6 U/L; p,0.001), Rai 1 (n = 27; mean:
28.16632.9 U/L; p,0.001) and Rai 2-3-4 (n = 45; mean:
72.886101.1 U/L; p,0.001). We also noticed significant differ-
ence in TK1 activity between Rai 0 and Rai 2-3-4 stages
(p,0.001) and Rai 1 and Rai 2-3-4 stages (p = 0.002) (Figure 3).
CLL patients were on average 65.6 years old (range: 46–86).
There was no difference in TK1 levels upon comparing those
below and equal to 60 years (middle aged, n = 29) and those over
60 years (elderly, n = 86) of age belonging to the different Rai
stages (Table 3).
The area under the receiver operating characteristic curve
(ROC-AUC) for TK1 was 0.840 (95% CI: 0.787–0.892) for
differentiating CLL patients from age and sex matched healthy
controls, with a cut-off value of 10.5 U/L (sensitivity: 80.9%,
specificity: 73.4%) (Figure 4A.). Furthermore, at the same cut-off
value, the ROC-AUC for TK1 was 0.760 (95% CI: 0.671–0.849)
for differentiating Rai 0 stage CLL patients from healthy controls
(sensitivity: 73.9%, specificity: 72.1%) (Figure 4B.).
We also compared the TK1 results of the CLL patients with
other known prognostic factors, i.e., CD38 and Zap70 expression.
The mean TK1 activity in the CD38–/Zap70– group (n = 52) was
significantly lower than that in the CD38+/Zap70+ group (n = 31)
(22.3617.8 U/L vs. 1096130.3 U/L; p,0.001). The difference
was also significant between the CD38–/Zap70+ group (n = 17)
and the CD38+/Zap70+ group (26.25633 U/L vs.
1096130.3 U/L; p = 0.002); and between the CD38+/Zap70–
group (n = 15) and the CD38–/Zap70– group (40.87638 U/L vs.
22.3617.8 U/L; p = 0.022); and the CD38–/Zap70+ group and
the CD38+/Zap70– group (26.25633 U/L vs. 40.87638 U/L;
p = 0.021) (Figure 5.).
With ROC analysis, the TK1 cut-off value to distinguish
CD38–/Zap70– patients from those with either or both positivity
was 30 U/L (ROC-AUC: 0.710, 95%CI: 0.601–0.819, Specific-
ity:76.6%, Sensitivity: 54.3%).
Out of 115 CLL patients, 95 had FISH data. Upon comparing
those with no chromosomal alterations, del(13q), 12 trisomy
(n = 76) with the group with del(17p13), del(11q22) (n = 19) no
statistically significant difference was found in the TK1 values
(38.7665.7 U/L vs. 55.5696.5 U/L, p = 0.347). The non-
significance did not change when patients with 12 trisomy were
excluded from the statistical analysis (33.0644.5 vs. 55.5696.5, p
= 0.211).
We observed a statistically significant correlation between TK1
activity and WBC (Spearman’s rho: 0.367, p,0.001) and absolute
B cell count (Spearman’s rho: 0.369, p,0.001).
Discussion
According to the 2008 guideline of the Clinical Laboratory
Standards Institute, it may be necessary to carry out a minor
reference value study to validate a reference interval given by the
test manufacturer or a donor laboratory [37]. Soon after we
Table 1. Inter-assay and Intra-assay precision and accuracy
for serum thymidine kinase activity of QC1 and QC2 samples.
Nominal concentration (U/L)
14.8 (QC1) 53.7 (QC2)
Observed concentration (U/L)
Intra-assay mean 6 SD 15.061.58 62.466.34
Intra-assay precision (%CV) 10.54 10.16
Intra-assay accuracy (%DFN) 1.35 16
Inter-assay mean 6 SD 14.862.23 49.1566.27
Inter-assay precision (%CV) 15.03 12.76
Inter-assay accuracy (%DFN) 0 –8.5
SD, standard deviation; %CV, percent coefficient of variation; %DFN, percent
deviation from nominal value.
doi:10.1371/journal.pone.0091647.t001
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Figure 2. Age-related frequency distributions of serum thymidine kinase activity in age groups 18–35 years (A), 35–60 years (B) and
60–86 years (C). Box and whisker plots showing significant difference of serum TK activity in the studied age groups (D).
doi:10.1371/journal.pone.0091647.g002
Table 2. CLL patient characteristics.
CLL patients (n =115)
Age, years (mean, range) 65.6 (46–86)
Males (n, %) 61 (53)
Females (n, %) 54 (47)
Rai 0 (n, %) 43 (37)
Rai 1 (n, %) 27 (23)
Rai 2 (n, %) 19 (17)
Rai 3 (n, %) 15 (13)
Rai 4 (n, %) 11 (10)
CD38–/Zap70– (n, %) 52 (45)
CD38–/Zap70+ (n,%) 17 (15)
CD38+/Zap70– (n, %) 15 (13)
CD38+/Zap70+ (n, %) 31 (27)
White blood cell count, G/L (mean, range)50.6 (12.4–447)
Absolute B cell count, G/L (mean, range) 39.9 (5.2–392)
doi:10.1371/journal.pone.0091647.t002
Figure 3. Comparison of serum thymidine kinase activity in de
novo CLL patients in Rai 0, Rai 1 and Rai 2-3-4 clinical stages
with the age and sex matched healthy cohort.
doi:10.1371/journal.pone.0091647.g003
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started our TK1 measurements with the test manufacturer’s
reference range (2 – 7.5 U/L) it turned out that it was not
applicable to our population, as we often observed higher TK1
activity than the suggested upper reference limit even in healthy
individuals. The interpretation of these results was not always
convincing and caused some unnecessary anxiety for physicians
and patients. The observed elevated TK1 activity in our healthy
population and the significant differences in TK1 activity between
the age groups encouraged us to define our own reference ranges
for TK1. Although TK1 measurements are widely used in
malignant diseases for prognostic purposes and even in routine
health screening [38], to our knowledge no age-related reference
ranges have been published so far for TK1 activity.
In each age group we had sufficient numbers of reference
subjects to determine the 97.5 percentiles. Based on our 97.5
percentile results, the suggested reference values are ,30 U/L for
young (18–35 years), ,25 U/L for middle-aged (36–60 years) and
,19 U/L for elderly (60–86 years) adults. The age-specific
reference ranges may be crucial in the context of chronic
lymphocytic leukemia, where most of the affected are older
individuals. We also identified a cutoff point of 10.5 U/L
distinguishing CLL patients in the RAI 0 stage from healthy
individuals. This result correlates well with the finding of Letestu et
al, who found a serum TK1 activity of 10 U/L to be an
independent predictor of progression-free survival with a hazard
ratio of 2.98, p,0.0001 [39].
As TK1 is a general proliferation marker, several non-malignant
conditions like infection, inflammation, autoimmune disorders and
benign tissue proliferations might also cause mildly elevated TK1
levels [40]. Hagberg et al showed that severe vitamin B12
deficiency caused elevated serum TK1 levels, as the proliferating
tissues became unstable in the absence of the vitamin [41]. Chen et
al also showed that serum TK1 concentration was useful in health
screening as their patients with elevated TK1 concentration had a
significantly increased risk of developing malignancies [42]. The
above study also showed that a significantly larger proportion of
oilfield workers had elevated serum TK1 concentrations than city
dwellers [42]. As such, in routine medical practice, non-malignant
medical conditions and environmental factors need to be
considered when using TK1 as a health screening marker.
It is also known that CD38+ CLL has a more adverse prognosis
[43]. Hus et al showed that CD38 combined with Zap70
expression amplified the prognostic power of both markers. They
found that Zap70+/CD38+ patients had shorter event-free
survival than CD38–/Zap70– patients [44]. In our study, we
found significantly higher TK1 activity in CD38+/Zap70+ as
compared to CD38–/Zap70– patients and there was no significant
difference between CD38–/Zap70– and CD38–/Zap70+ patients.
Higher serum TK1 activities of CD38+ CLL patients can be
Table 3. Comparison of thymidine kinase activity between middle-aged and elderly CLL patients belonging to different Rai stages.
Rai stages Age p values
46–60 years 60.1–86 years
Thymidine kinase activity, mean ± SD (U/L)
Rai 0 (n = 43) 15.568.9 (n = 15) 20.2618.2 (n = 28) 0.558
Rai 1 (n = 27) 59.7667.7 (n = 5) 21.0613.3 (n = 22) 0.524
Rai 2, 3 or 4 (n = 45) 89.06151.6 (n = 9) 68.8686.7 (n = 36) 0.645
doi:10.1371/journal.pone.0091647.t003
Figure 4. Receiver operating characteristic (ROC) analysis of serum thymidine kinase activity for differentiating all CLL patients (A)
and Rai 0 CLL patients (B) from age and sex matched healthy controls. AUC, area under the receiver operating characteristic curve.
doi:10.1371/journal.pone.0091647.g004
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explained by the intense proliferation of cells, as both TK1 and
CD38 are proliferation markers [45,35].
Furthermore, in line with published data, del(13q), 12 trisomy,
del(17p13) and del(11q22) FISH aberrations did not influence
TK1 values in our patients [16].
TK1 activity correlated with WBC and absolute B cell count in
our study, this finding supports the data reported previously by
Hallek et al [15].
Each laboratory should establish its own age-related reference
ranges as even minor ethnical or lifestyle differences in a particular
region may have a significant impact on reference ranges, not
disregarding the influence of age and sex. These differences make
it difficult to obtain universally applicable reference intervals, even
though the applied methodology is traceable to reference
measurement systems [46,47]. As producing reference ranges is
an expensive task for an individual laboratory, one possible
solution is to establish reference ranges for a homogeneous
population by involving all the laboratories measuring the certain
analyte with the same method [47]. Siest et al emphasized that the
boundaries between healthy and pathological conditions are not
clear-cut, and reference intervals or cut-off values should be
established to expedite clinical decision making [48].
Limitations of the present results include the cross-sectional
nature of the CLL study, a prospective design would have enabled
us to examine the utility of TK1 as a prognostic marker. Although
the CLL population was represented by a cohort of 115 de novo
patients, the non-similar number of patients in the different Rai
stages, and as per their CD38 and Zap70 characteristics may have
distorted the statistical findings. Furthermore, our age-specific
reference ranges need to be validated in other healthy populations
as well.
In conclusion, serum TK1 levels decline significantly with age in
the healthy, and this finding warrants the use of age-related
reference ranges. Furthermore, it may distinguish CLL patients in
the RAI 0 stage from healthy individuals in the diagnostic work-up
of CLL suspect cases.
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